Despite advances that have improved survival after allogeneic hematopoietic stem cell transplantation (HCT), chronic graft-versus-host disease (GVHD) remains a leading cause of late morbidity and mortality after transplant. Current treatment options show limited efficacy in steroid-refractory disease, and...
In GVHD, the donor cells attack your normal, healthy tissue. There are treatments for GVHD. Ask your care team about the possible side effects or complications of HCT and how this might affect your quality of life. More information on GVHD can be found at NCCN.org/patientguidelines and on...
211 The adverse impact of chronic GVHD (cGvHD) on health and quality of life is especially critical in children because of their longer life expectancy and problems impacting growth and development. Although risk-factors for developing cGvHD in children are reported, little is known about risk ...
An increased use of reduced-intensity allogeneic BMT has resulted in a decrease in transplant-related mortality, although the risk of GVHD may be higher.97 The use of alemtuzumab, antithymocyte globulin, and post-transplantation cyclophosphamide has also resulted in a significant decrease in both ...
and safety of MSCs, MSC infusion could be designed in combination with other GVHD prophylactic regimens, such as low-dose PTCy and T cell–depleted haploidentical HSCT, to further decrease the incidence of GVHD after haplo-HSCT and improve the life expectancy and quality of life of the ...
In the ideal scenario in which the patient achieves good remission before transplantation, GvHD prophylaxis with anti-thymocyte globulin, methotrexate, and cyclosporine is recommended whatever the graft source. pCML-WP recommendation Myeloablative conditioning is recommended. The choice of conditioning ...
These results may indicate improved HLA typing, GvHD prophylaxis and treatment for infectious episodes. In comparison, in the LEUK+ cohort a dramatic improvement was documented with an increase of survival rate from 27 % to 83% indicating the additional impact of a shortened time interval between ...
Although acute GVHD (aGVHD) has a considerable impact on nonrelapse mortality (NRM), chronic GVHD (cGVHD) is the most common long-term complication and occurs in 30% to 70% of adults who survive for more than 100 days after receiving their transplantation [3]. cGVHD has been associated ...
Sixty-three patients (60%) had received calcineurin inhibitor (CNI) with or without a steroid immediately before the onset of chronic GVHD, whereas 26 patients (25%) had not received any IST. After onset of cGVHD, 29 patients did not receive any new or additional systemic IST because of ...
HSCT Chronic GVHD Monoclonal antibody 1. Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potential cure for many high-risk hematological malignancies, and an increasing number of patients have benefited from this treatment and achieved a longer life expectancy [1,...